Yanay Geva’s Post

AstraZeneca will acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs). The $2.4B #acquisition marks a major step forward in #AstraZeneca delivering on its ambition to transform #cancer outcomes. RCs provide a more precise mechanism of cancer cell killing compared with traditional radiation therapy. Fusion’s lead drug is being developed for metastatic #prostatecancer and is currently in Phase 2. The deal is the third recent buyout of a radiopharmaceutical developer in recent months, following similar deals from Eli Lilly and Company and Bristol Myers Squibb. #oncology

In business news, ArriVent Biopharma, Inc. announced that the Company has entered into a collaboration agreement with Jiangsu Alphamab Biopharmaceuticals Co., Ltd., a wholly owned subsidiary of Alphamab Oncology, to discover, develop and commercialize novel antibody-drug conjugates for the treatment of cancers. Under the agreement, both companies will leverage Alphamab’s proprietary linker-payload platform and glycan-conjugation technology to identify novel ADCs for oncology indications. The agreement gives ArriVent exclusive rights to develop and commercialize ADCs globally, except greater China, which includes outside of mainland China, Hong Kong, Macau and Taiwan where Alphamab retains the right to develop and commercialize the ADCs. The terms of the agreement include combined upfront and potential milestone payments to Alphamab of up to $615.5 million in aggregate for the potential programs, based on the achievement of certain regulatory, development, and sales milestones. In addition, Alphamab is entitled to receive tiered sales royalties from ArriVent for each ADC product. #mabs https://lnkd.in/e-xg3hHZ

Novartis, a pharmaceutical company, agreed to acquire Mariana Oncology, a fully integrated biotechnology company pioneering a new era of radiopharmaceutical innovation to treat people with cancer, for $1.75bn. “Novartis is an established leader in the commercialization of radiopharmaceuticals with a world-class team and global reach. Together, we offer a compelling combination of capabilities. In the short time since founding the company, the team at Mariana Oncology has developed a leading radiopharmaceutical discovery platform and an innovative pipeline. Our strategy has centered on overcoming the unique challenges of end-to-end radiopharmaceutical R&D and ultimately, delivery of these drugs to the bedside. Both Mariana and Novartis are committed to transforming cancer care, and together we will be in a better position to do that,” Simon Read, Mariana Oncology Founder and CEO. Mariana Oncology led by Simon Read is advised by Centerview Partners, Goodwin, and ICR Westwicke (led by Christopher Brinzey). Novartis led by Shiva Malek. #MergersAcquisitionsDivestitures #Biotechnology #Pharmaceutical

The cancer drug market is thriving, and the companies are betting on Antibody Drug Conjugates (ADCs) with their potential to lower toxicity compared to standard chemotherapy. Clinical research success is positioning ADCs as the standout winner in 2023, marked by numerous acquisitions and deals within the pharmaceutical and biotech sectors to bolster their portfolios. This renewed interest in ADCs is expected to continue in 2024 but would depend on the ongoing ADCs clinical trial results. #drugdiscovery #drugdevelopment Check out the full story:

#AstraZeneca plans to build a $1.5 billion manufacturing facility in Singapore for antibody drug conjugates (ADCs), enhancing global supply of its ADC portfolio. #ADCs are next-generation treatments that use targeted antibodies to take powerful cancer-battling agents to cancer cells directly. This move highlights the importance of ensuring pharmaceutical companies have production facilities in local markets, creating a smoother supply chain and further cement their regional influence. Design and construction of the manufacturing facility will start by the end of 2024, with targeted operational readiness from 2029, with support from the Singapore Economic Development Board (EDB). #Pharmaceuticals #LifeSciences #Cancer #ADCs

#News: ONO PHARMACEUTICAL CO., LTD. said Monday it will pay $2.4 billion to acquire Deciphera Pharmaceuticals for #cancerdrugs that could generate peak annual sales of more than $1 billion. Boston-based #Deciphera has accepted an offer of $25.60 per share, a more than 70% premium over its closing price Friday. In return, #Ono will take control of one authorized drug, one near-approval molecule and infrastructure for commercializing the assets. Deciphera won FDA approval for the #tyrosinekinaseinhibitor #Qinlock (#ripretinib) in 2020. The approval covered the use of Qinlock in adults with advanced #gastrointestinalstromaltumor (#GIST) who have received prior treatment with three or more kinase inhibitors including #imatinib, the drug Novartis sells as #Gleevec. The European Medicines Agency authorized Qinlock in 2021. Qinlock generated 25% growth in the U.S. and a 33% jump in overseas sales in 2023. Globally, sales topped $159 million. Deciphera attributed the growth to strong demand in the fourth-line setting, off-label use in earlier lines of GIST and the increased average duration of therapy. The company tipped the same factors to drive growth in 2024. Read more from BioSpace 👇🏼 https://lnkd.in/ejtfRBUG

📰 In another #strategic move on its Oncology pipeline, Merck is set to acquire a key asset from a privately held biopharma company, Curon Biopharmaceutical. 🍎 The apple of their eye? An Investigational B-Cell Depletion Therapy, CN201, a next-gen bispecific, with applications spanning B-cell malignancies and autoimmune disorders. Currently, clinical programs (PI/Ib/II) are underway for NHL, and B-cell ALL. A strategic move to diversify Oncology assets, as the company considers how the Oncology portfolio will thrive once #Keytruda loses patent exclusivity. #Oncology #Merck #BCellMalignancies #NonHodgkinsLymphoma #NHL #AcuteLymphocyticLeukemia #ALL #Curon #Biotech #Biopharma #CorporateAffairs #Pharma #Healthcare https://lnkd.in/en9gzdwE

Ono Pharmaceutical Acquires Deciphera for $2.4 Billion to Bolster Oncology Portfolio ONO PHARMACEUTICAL CO., LTD. of Japan is set to acquire Deciphera Pharmaceuticals, a Massachusetts-based biopharmaceutical company, for $2.4 billion. This move highlights a significant investment in the oncology sector, primarily driven by Deciphera's robust pipeline and its existing cancer drug, Qinlock. Qinlock, specifically targeting gastrointestinal stromal tumor (GIST) as a fourth-line treatment, generated $159.1 million in revenue for 2023. The acquisition includes a premium of nearly 75% over Deciphera's recent stock closing price, reflecting the high value placed on its advanced kinase inhibitor-focused technology and market presence. Deciphera's pipeline includes several promising candidates like vimseltinib, which recently showed positive results in a Phase 3 trial for tenosynovial giant cell tumors and is approaching FDA submission. Additionally, DCC-3116, another kinase inhibitor targeting ULK1/2 for inhibiting autophagy, is progressing through clinical trials. These developments underscore Deciphera's scientific capabilities in pioneering treatments for complex cancers. The strategic acquisition allows Ono to significantly enhance its oncology portfolio and strengthen its position in key international markets, particularly in the United States and Europe. This aligns with Ono's broader objective of becoming a global specialty pharmaceutical leader. The merger is not only a testament to Deciphera’s scientific and commercial achievements but also positions Ono to leverage Deciphera's innovative treatments and research capabilities to accelerate its business development and research in kinase drug discovery. This deal, though substantial, is part of a larger trend of strategic acquisitions within the biopharmaceutical industry, aimed at bolstering pipeline capabilities and enhancing global market reach. For Ono, which has a history of successful collaborations like with Bristol Myers Squibb on the PD-1 drug Opdivo, acquiring Deciphera provides a ready suite of advanced therapies and a significant boost to its research and commercialization efforts in the oncology domain. Sources: Business Wire, Fierce Pharma (29.4.24) #biopharma #insights #oncology

ImmunityBio, Inc. has started the year off strong by announcing it has entered into a deal with Oberland Capital involving a $320m revenue interest purchase agreement (RIPA). The investment will advance the company’s commercialisation of its near-approval bladder cancer drug candidate, Anktiva (N-803), and support ImmunityBio’s efforts to expand Anktiva into multiple solid tumour indications. Read the full article below on Pharmaceutical-Technology: #globaldata #pharmaceuticaltechnology #pharmaceuticals #pharmanews #bladdercancer #cancerresearch #oncology #drugdevelopment https://lnkd.in/ggJTBJRp